Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis.

OBJECTIVE: This study sought to determine the effect of the recombinant human growth hormone (rhGH) treatment of Turner syndrome (TS) on height outcome.

METHODS: We searched in MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews. A literature search identified 640 records. After screening and full-text assessment, 11 records were included in the systematic review. Methodological quality was assessed using the Cochrane Risk of Bias tool. RevMan 5.3 software was used for meta-analysis. We also assessed the quality of evidence with the GRADE system.

RESULTS: Compared with controls, rhGH therapy led to increased final height (MD = 7.22 cm, 95% CI 5.27-9.18, P  < 0.001, I 2 = 4%; P  = 0.18), height standard deviation (HtSDS) (SMD = 1.22, 95% CI 0.88-1.56, P  < 0.001, I 2 = 49%; P  = 0.14) and height velocity (HV) (MD 2.68 cm/year; 95% CI 2.34, 3.02; P  < 0.001, I 2 = 0%; P  = 0.72). There was a small increase in bone age (SMD 0.32 years; 95% CI 0.1, 0.54; P  = 0.004, I 2 = 73%; P  = 0.02) after rhGH therapy for 12 months. What is more, the rhGH/oxandrolone combination therapy suggested greater final height (MD 2.46 cm; 95% CI 0.73, 4.18; P  = 0.005, I 2 = 32%; P  = 0.22), increase and faster HV (SMD 1.67 cm/year; 95% CI 1.03, 2.31; P  < 0.03, I 2 = 80%; P  < 0.001), with no significant increase in HtSDS and bone maturation compared with rhGH therapy alone.

CONCLUSIONS: For TS patients, rhGH alone or with concomitant use of oxandrolone treatment had advantages on final height.